![]() ![]() ![]() Results Of the 203 participants (median age, 68 years median type 1 diabetes duration, 36 years 52% female 53% insulin pump use mean HbA 1c, 7.5% ), 83% used CGM at least 6 days per week during month 6. There were 31 prespecified secondary outcomes, including additional CGM metrics for hypoglycemia, hyperglycemia, and glucose control hemoglobin A 1c (HbA 1c) and cognition and patient-reported outcomes, with adjustment for multiple comparisons to control for false-discovery rate. Main Outcomes and Measures The primary outcome was CGM-measured percentage of time that sensor glucose values were less than 70 mg/dL during 6 months of follow-up. Interventions Participants were randomly assigned in a 1:1 ratio to use CGM (n = 103) or standard BGM (n = 100). Objective To determine whether CGM is effective in reducing hypoglycemia compared with standard blood glucose monitoring (BGM) in older adults with type 1 diabetes.ĭesign, Setting, and Participants Randomized clinical trial conducted at 22 endocrinology practices in the United States among 203 adults at least 60 years of age with type 1 diabetes. Importance Continuous glucose monitoring (CGM) provides real-time assessment of glucose levels and may be beneficial in reducing hypoglycemia in older adults with type 1 diabetes. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.Parallel Line Plot of Percent Time <70 mg/dL Visit Completion by Treatment GroupĮFigure 2. Cognitive Assessment and Patient-Reported OutcomesĮFigure 1. Subgroup Analysis for Percent Time Spent <70 mg/dL by Baseline CharacteristicsĮTable 19. Glycemic Outcomes Among Participants Using Injections for Insulin DeliveryĮTable 16. Glycemic Outcomes Among Participants Using a Pump for Insulin DeliveryĮTable 15. Per-Protocol Analysis of Percent Time <70 mg/dLĮTable 13. Real-time CGM Use by Pump and MDI UsersĮTable 12. ![]() Types of Medications at EnrollmentĮTable 9. ![]() Baseline Characteristics by Pump and MDI UsersĮTable 6. Description of Cognitive Assessment and Patient-Reported OutcomesĮTable 4. Eligibility and Exclusion CriteriaĮTable 2. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |